Transitioning to a subscription-style business model that assures a needed antibiotic will be there to combat resistance, while providing a predictable return on investment regardless of the volume of antibiotics used, would reduce the economic barriers that currently stymie the creation of new antibiotic treatments. Health care facilities and clinicians also need to use antibiotics appropriately to prevent the development of resistance and ensure antibiotics remain effective for as long as possible. The threat of antimicrobial resistance is real, and the consequences of inaction will be a devastating blow to modern medicine unless policymakers, public health, health care providers and pharmaceutical companies commit to sustained, collaborative efforts and investment toward solutions.